Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4

[1]  D. O'Shannessy,et al.  Expression of Folate Receptor-&agr; (FRA) in Gynecologic Malignancies and its Relationship to the Tumor Type , 2013, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[2]  E. Sausville,et al.  Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. V. van Meerbeeck,et al.  Mesothelin levels in urine are affected by glomerular leakage and tubular reabsorption. , 2012, Clinical lung cancer.

[4]  M. Edelman,et al.  Multicenter Trial of EC145 in Advanced, Folate-Receptor Positive Adenocarcinoma of the Lung , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  D. O'Shannessy,et al.  Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease , 2012, SpringerPlus.

[6]  J. Beta,et al.  HE4 protein and SMRP: Potential novel biomarkers in ovarian cancer detection. , 2012, Oncology letters.

[7]  M. Schummer,et al.  Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. , 2012, Gynecologic oncology.

[8]  S. Singhal,et al.  Folate Receptor Alpha Expression in Lung Cancer: Diagnostic and Prognostic Significance , 2012, Oncotarget.

[9]  Y. Hamuro,et al.  Characterization of the Human Folate Receptor Alpha Via Novel Antibody-Based Probes , 2011, Oncotarget.

[10]  R. Molina,et al.  Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. , 2011, Clinical chemistry.

[11]  I. Shih,et al.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. , 2011, Human pathology.

[12]  P. Low,et al.  The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer , 2011, Cellular Oncology.

[13]  I. Hellstrom,et al.  fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma. , 2011, Expert opinion on medical diagnostics.

[14]  Ashok Agarwal,et al.  Potential Markers for Detection and Monitoring of Ovarian Cancer , 2011, Journal of oncology.

[15]  J. Creaney,et al.  Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden , 2010, Clinical Cancer Research.

[16]  S. Larson,et al.  Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor α, in Epithelial Ovarian Cancer: a Phase I Study , 2010, Clinical Cancer Research.

[17]  M. Tsao,et al.  Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Nackaerts,et al.  Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. , 2010, American journal of respiratory and critical care medicine.

[19]  P. Low,et al.  Functional Folate Receptor Alpha Is Elevated in the Blood of Ovarian Cancer Patients , 2009, PloS one.

[20]  G. Anderson,et al.  Influence of Ovarian Cancer Risk Status on the Diagnostic Performance of the Serum Biomarkers Mesothelin, HE4, and CA125 , 2009, Cancer Epidemiology Biomarkers & Prevention.

[21]  M. Werner,et al.  Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. , 2008, Anticancer research.

[22]  Qin He,et al.  Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. , 2008, Gynecologic oncology.

[23]  G. Anderson,et al.  Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Postmenopausal Women at High-Risk for Ovarian Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[24]  Richard G. Moore,et al.  Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. , 2008, Gynecologic oncology.

[25]  P. Low,et al.  Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. , 2008, Human pathology.

[26]  P. Low,et al.  Folate receptor alpha as a tumor target in epithelial ovarian cancer. , 2008, Gynecologic oncology.

[27]  Thorsten Verch,et al.  The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. , 2008, Gynecologic oncology.

[28]  M. Sonobe,et al.  Expression Status of Folate Receptor α Is Significantly Correlated with Prognosis in Non-Small-Cell Lung Cancers , 2008, Annals of Surgical Oncology.

[29]  R. Bast,et al.  Early Detection of Ovarian Cancer , 2007, Disease markers.

[30]  Richard G. Moore,et al.  Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. , 2007, Gynecologic oncology.

[31]  Z. Yue,et al.  Serum tumour markers in patients with chronic kidney disease , 2007, Scandinavian journal of clinical and laboratory investigation.

[32]  Mitchell Ho,et al.  Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors , 2006, Molecular Cancer.

[33]  Kazuhisa Takahashi,et al.  Novel ELISA system for detection of N‐ERC/mesothelin in the sera of mesothelioma patients , 2006, Cancer science.

[34]  Mitchell Ho,et al.  Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma , 2006, Clinical Cancer Research.

[35]  H. Frierson,et al.  Comprehensive analysis of HE4 expression in normal and malignant human tissues , 2006, Modern Pathology.

[36]  N. Sardesai,et al.  Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic Marker , 2006, Cancer Epidemiology Biomarkers & Prevention.

[37]  Yinhua Yu,et al.  Potential markers that complement expression of CA125 in epithelial ovarian cancer. , 2005, Gynecologic oncology.

[38]  Jan Holm,et al.  Megalin binds and mediates cellular internalization of folate binding protein , 2005, The FEBS journal.

[39]  K A Baggerly,et al.  New tumor markers: CA125 and beyond , 2005, International Journal of Gynecologic Cancer.

[40]  Mitchell Ho,et al.  New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA , 2005, Clinical Cancer Research.

[41]  P. Low,et al.  Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. , 2005, Analytical biochemistry.

[42]  Christopher P Crum,et al.  Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. , 2005, Cancer research.

[43]  N Urban,et al.  Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. , 2004, Gynecologic oncology.

[44]  E. Glezer,et al.  Clinical and Biological Applications of ECL , 2004 .

[45]  Robert C. Bast,et al.  Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis , 2004, Clinical Cancer Research.

[46]  N. Umesaki,et al.  Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion* , 2004, Journal of Biological Chemistry.

[47]  A. Musk,et al.  Mesothelin-family proteins and diagnosis of mesothelioma , 2003, The Lancet.

[48]  Michèl Schummer,et al.  The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. , 2003, Cancer research.

[49]  N. Ordóñez.  Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma , 2003, Modern Pathology.

[50]  U Menon,et al.  Factors influencing serum CA125II levels in healthy postmenopausal women. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[51]  D. Sugarbaker,et al.  The α folate receptor is highly activated in malignant pleural mesothelioma , 2001 .

[52]  Z. Ye,et al.  Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[53]  W. Gunning,et al.  Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[54]  A. Russo,et al.  Expression of folate binding protein as a prognostic factor for response to platinum‐containing chemotherapy and survival in human ovarian cancer , 1998, International journal of cancer.

[55]  G Toffoli,et al.  Overexpression of folate binding protein in ovarian cancers , 1997, International journal of cancer.

[56]  Markman.  The Role of CA-125 in the Management of Ovarian Cancer. , 1997, The oncologist.

[57]  I. Pastan,et al.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[58]  N. Yamaguchi,et al.  Molecular Cloning and Expression of Megakaryocyte Potentiating Factor cDNA (*) , 1995, The Journal of Biological Chemistry.

[59]  S. Thylan.  Prospective multicenter study on CA 125 in postmenopausal pelvic masses. , 1995, Gynecologic oncology.

[60]  C. Meijer,et al.  Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue. , 1995, Journal of clinical pathology.

[61]  J. Ross,et al.  Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications , 1994, Cancer.

[62]  N. Yamaguchi,et al.  A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. , 1994, The Journal of biological chemistry.

[63]  V. Zurawski,et al.  Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. , 1992, Cancer research.

[64]  L R Coney,et al.  Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. , 1992, Cancer research.

[65]  D. Goldenberg,et al.  Normal tissue reactivity of four anti‐tumor monoclonal antibodies of clinical interest , 1991, International journal of cancer.

[66]  P. Kenemans,et al.  Comparative Immunohistochemical Study of Four Monoclonal Antibodies Directed Against Ovarian Carcinoma‐Associated Antigens , 1991, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[67]  S. Ménard,et al.  Immunohistochemical Reactivity of a Monoclonal Antibody Prepared against Human Ovarian Carcinoma on Normal and Pathological Female Genital Tissues , 1989, Tumori.

[68]  S. Doniņa,et al.  Urinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer: a case--control study. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[69]  H. Labib,et al.  HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. , 2010, Asian Pacific journal of cancer prevention : APJCP.

[70]  M. Maeda,et al.  Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. , 2008, Oncology reports.

[71]  I. Hellstrom,et al.  SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. , 2008, Advances in experimental medicine and biology.

[72]  Mitchell Ho,et al.  Mesothelin targeted cancer immunotherapy. , 2008, European journal of cancer.

[73]  D. Sugarbaker,et al.  The alpha folate receptor is highly activated in malignant pleural mesothelioma. , 2001, The Journal of thoracic and cardiovascular surgery.

[74]  P. Bunn,et al.  New anti‐lung‐cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma , 1994, International journal of cancer. Supplement = Journal international du cancer. Supplement.